{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T22:13:09Z","timestamp":1761862389039},"reference-count":24,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2004,11,1]],"date-time":"2004-11-01T00:00:00Z","timestamp":1099267200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Bone"],"published-print":{"date-parts":[[2004,11]]},"DOI":"10.1016\/j.bone.2004.07.003","type":"journal-article","created":{"date-parts":[[2004,9,24]],"date-time":"2004-09-24T11:56:47Z","timestamp":1096027007000},"page":"1038-1045","source":"Crossref","is-referenced-by-count":61,"title":["Intravenous pamidronate treatment of children under 36 months of age with osteogenesis imperfecta"],"prefix":"10.1016","volume":"35","author":[{"given":"L.A.","family":"DiMeglio","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Ford","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"McClintock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Peacock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.bone.2004.07.003_bib1","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1136\/jmg.16.2.101","article-title":"Genetic heterogeneity in osteogenesis imperfecta","volume":"16","author":"Sillence","year":"1979","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.bone.2004.07.003_bib2","series-title":"The metabolic and molecular bases of inherited disease","first-page":"5241","article-title":"Disorders of collagen biosynthesis and structure","author":"Byers","year":"2001"},{"issue":"1","key":"10.1016\/j.bone.2004.07.003_bib3","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0950-351X(97)80601-5","article-title":"Osteogenesis imperfecta and other heritable disorders of bone","volume":"11","author":"Paterson","year":"1997","journal-title":"Bailliere's Clin. Endocrinol. Metab."},{"issue":"5","key":"10.1016\/j.bone.2004.07.003_bib4","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1007\/BF00350961","article-title":"Radiological manifestations of bisphosphonate treatment with APD in a child suffering from osteogenesis imperfecta","volume":"16","author":"Devogelaer","year":"1987","journal-title":"Skelet. Radiol."},{"issue":"1","key":"10.1016\/j.bone.2004.07.003_bib5","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1097\/01241398-198801000-00017","article-title":"Is APD a promising drug in the treatment of severe osteogenesis imperfecta?","volume":"8","author":"Huaux","year":"1988","journal-title":"J. Pediatr. Orthop."},{"issue":"4","key":"10.1016\/j.bone.2004.07.003_bib6","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/S0022-3476(97)70074-X","article-title":"Intravenous pamidronate treatment in osteogenesis imperfecta","volume":"131","author":"Bembi","year":"1997","journal-title":"J. Pediatr."},{"issue":"4","key":"10.1016\/j.bone.2004.07.003_bib7","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1097\/00005792-199707000-00005","article-title":"Long-term effects of bisphosphonates on the growing skeleton. Studies of young patients with severe osteoporosis","volume":"76","author":"Brumsen","year":"1997","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.bone.2004.07.003_bib8","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1007\/s004310050715","article-title":"Treatment of osteogenesis imperfecta with the bisphosphonate olpadronate (dimethylaminohydroxypropylidene bisphosphonate)","volume":"156","author":"Landsmeer-Beker","year":"1997","journal-title":"Eur. J. Pediatr."},{"issue":"3","key":"10.1016\/j.bone.2004.07.003_bib9","first-page":"261","article-title":"Intravenous pamidronate treatment in osteogenesis imperfecta","volume":"157","author":"Fujiwara","year":"1998","journal-title":"Eur. J. Pediatr."},{"key":"10.1016\/j.bone.2004.07.003_bib10","first-page":"137","article-title":"Effects of intravenous pamidronate therapy on bone mineralization in osteogenesis imperfecta","volume":"50","author":"Gonzalez","year":"1998","journal-title":"Horm. Res."},{"issue":"5","key":"10.1016\/j.bone.2004.07.003_bib11","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1136\/adc.86.5.356","article-title":"Beneficial effect of long term intravenous bisphosphonate treatment of osteogenesis imperfecta","volume":"86","author":"Astrom","year":"2002","journal-title":"Arch. Dis. Child."},{"key":"10.1016\/j.bone.2004.07.003_bib12","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJM199810013391402","article-title":"Cyclic administration of pamidronate in children with severe osteogenesis imperfecta","volume":"339","author":"Glorieux","year":"1998","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.bone.2004.07.003_bib13","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1542\/peds.111.3.573","article-title":"Intravenous bisphosphonate therapy in children with osteogenesis imperfecta","volume":"111","author":"Falk","year":"2003","journal-title":"Pediatrics"},{"issue":"9419","key":"10.1016\/j.bone.2004.07.003_bib14","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/S0140-6736(04)16101-1","article-title":"Skeletal effects and functional outcome with olpadronate in children with osteogenesis imperfecta: a 2-year randomised placebo-controlled study","volume":"363","author":"Sakkers","year":"2004","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.bone.2004.07.003_bib15","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1210\/jc.85.5.1846","article-title":"Pamidronate treatment of severe osteogenesis imperfecta in children under 3 years of age","volume":"85","author":"Plotkin","year":"2000","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"3","key":"10.1016\/j.bone.2004.07.003_bib16","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1210\/jc.2002-021371","article-title":"Osteogenesis imperfecta types I, III, and IV: effect of pamidronate therapy on bone and mineral metabolism","volume":"88","author":"Rauch","year":"2003","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2004.07.003_bib17","unstructured":"Nigrin. D. Growth Calculator, 2.0. http:\/\/www.chip.org\/servlet\/GrowthCalc 2000. 7-1-2003."},{"key":"10.1016\/j.bone.2004.07.003_bib18","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/BF00297295","article-title":"Osteogenesis imperfecta: a clinical study of the first ten years of life","volume":"50","author":"Vetter","year":"1992","journal-title":"Calcif. Tissue Int."},{"issue":"1","key":"10.1016\/j.bone.2004.07.003_bib19","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/j.1651-2227.1998.tb01388.x","article-title":"Beneficial effect of bisphosphonate during five years of treatment of severe osteogenesis imperfecta","volume":"87","author":"Astrom","year":"1998","journal-title":"Acta Paediatr."},{"issue":"2","key":"10.1016\/j.bone.2004.07.003_bib20","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/S0022-3476(97)70162-8","article-title":"Urinary phosphate\/creatinine, calcium\/creatinine, and magnesium\/creatinine ratios in a healthy pediatric population","volume":"131","author":"Matos","year":"1997","journal-title":"J. Pediatr."},{"key":"10.1016\/j.bone.2004.07.003_bib21","doi-asserted-by":"crossref","first-page":"531","DOI":"10.3109\/17453677008991541","article-title":"Bone formation in human osteogenesis imperfecta, measured by tetracycline bone labeling","volume":"41","author":"Villanueva","year":"1970","journal-title":"Acta Orthop. Scand."},{"issue":"1","key":"10.1016\/j.bone.2004.07.003_bib22","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0022-3476(05)81038-8","article-title":"Hypercalciuria in children severely affected with osteogenesis imperfecta","volume":"119","author":"Chines","year":"1991","journal-title":"J. Pediatr."},{"issue":"9","key":"10.1016\/j.bone.2004.07.003_bib23","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1172\/JCI0215952","article-title":"The effects of intravenous pamidronate on the bone tissue of children and adolescents with osteogenesis imperfecta","volume":"110","author":"Rauch","year":"2002","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bone.2004.07.003_bib24","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1056\/NEJMoa023110","article-title":"Bisphosphonate-induced osteopetrosis","volume":"349","author":"Whyte","year":"2003","journal-title":"N. Engl. J. Med."}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328204002972?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328204002972?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,2,3]],"date-time":"2019-02-03T13:54:10Z","timestamp":1549202050000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328204002972"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,11]]},"references-count":24,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2004,11]]}},"alternative-id":["S8756328204002972"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2004.07.003","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2004,11]]}}}